Deciphera Pharmaceuticals (DCPH) Misses Q2 EPS by 6c

Deciphera Pharmaceuticals (NASDAQ: DCPH) reported Q2 EPS of ($1.21), $0.06 worse than the analyst estimate of ($1.15). Revenue for the quarter came in at $22 million versus the consensus estimate of $22 million.

For earnings history and earnings-related data on Deciphera Pharmaceuticals (DCPH) click here.

You May Also Be Interested In

• North American Construction (NOA) Tops Q2 EPS by 9c; Offers Guidance
• Pan American Silver (PAAS) Misses Q2 EPS by 19c
• Park Dental Partners, Inc. (PARK) Tops Q2 EPS by 28c